Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

January 2021; 8 (1) EditorialOpen Access

Obesity's role in MS

An intervention target with possible interactions

Kathryn C. Fitzgerald, View ORCID ProfileEllen M. Mowry
First published December 15, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000932
Kathryn C. Fitzgerald
From the Department of Neurology (K.C.F., E.M.M.), Johns Hopkins School of Medicine; and Department of Epidemiology (K.C.F., E.M.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen M. Mowry
From the Department of Neurology (K.C.F., E.M.M.), Johns Hopkins School of Medicine; and Department of Epidemiology (K.C.F., E.M.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ellen M. Mowry
Full PDF
Citation
Obesity's role in MS
An intervention target with possible interactions
Kathryn C. Fitzgerald, Ellen M. Mowry
Neurol Neuroimmunol Neuroinflamm Jan 2021, 8 (1) e932; DOI: 10.1212/NXI.0000000000000932

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
405

Share

  • Article
  • Info & Disclosures
Loading

In the accompanying study by Hedström et al., the investigators explore modifying effects of several well-known MS risk factors. They consider excess risk and synergistic effects of obesity, Epstein-Barr virus (EBV) infection, and genetic factors (human leukocyte antigen [HLA]-DRB1*15:01, primarily) on the risk of MS in 2 Swedish population-based cohorts. Findings describe that overweight and obesity in young adulthood confer a nonadditive effect on the risk of MS among those with a history of EBV infection or are HLA-DRB1*15:01 carriers.

Assuming a lack of bias, deviation from risk additivity suggests that some subgroups would theoretically benefit more (e.g., obtain a greater absolute risk reduction) from a specific intervention than other individuals would.1 In this case, the observed departure from additivity associated with obesity among EBV-infected or HLA-DRB1*15:01 carriers implies that reduction in body weight would be most beneficial for those with a previous history of EBV infection or carry HLA-DRB1*15:01 alleles. Further excess risk above additivity for multiple exposures (e.g., superadditivity, or the 3-way interactions tested here) may be particularly valuable from a preventive medicine perspective because risk for the outcome could be theoretically be reduced considerably by intervening on either exposure, assuming both are causal and modifiable.1,2

As with most epidemiologic research, some assumptions and data requirements are necessary to obtain valid inference. Those related to interaction rely intricately on adequate control of confounding and, often, rely on large effects of the study exposures in question to make reliable conclusions pertaining to biologic interaction.1,2 Relatedly, a large sample size is also necessary, particularly in the context of assessment of risk superadditivity1 (3-way interactions) included in this report. Herein, these conditions were relatively true. Some of study design elements, however, may potentially have introduced bias. The median disease duration at enrollment was 2 and 18 years for the 2 included cohorts, which may affect the interpretability of the EBV nuclear antigen-1 titers. Relatedly, the assessment of body mass index at age 20 years, infectious mononucleosis history, and some of the other confounders was retrospective and self-reported. Last, 1 additional concern is the differential response rates in cases and control populations potentially inducing some selection bias; the prevalence of obesity or the distribution of body weight (or other potential confounders) may differ among those who respond to the survey vs those who do not, especially in the non-MS controls.

The reproducibility of the observed interaction effects (especially for observed 3-way interactions) in other populations would be a valuable next step; some studies in non-Northern European populations do not observe excess risk of MS for HLA-DRB1*15:01 carriers associated with EBV infection.3,4 Furthermore, exploration of the dose-response for early adulthood body mass index, incorporating more flexible modeling strategies (rather than the dichotomous overweight vs nonoverweight), would additionally bolster the findings.

Identification of underlying mechanisms of interaction depends on biologic assumptions that are often difficult to verify using epidemiologic data alone, even in the context of large effect sizes, optimal data, and control for confounding. For this study, detailed information describing the biological mechanisms that might explain the findings is not well known. Some hypothesized mechanisms include that an already primed proinflammatory immune system in people with high genetic risk for MS (e.g., HLA-DRB1*15:01 carriers), or among those with previous EBV infection, is exaggerated by the low-grade inflammatory state observed in obese individuals, which then confers an excess risk for MS.5,–,8 It is important to note that the genetic burden of MS risk and EBV infection (outside the context of an effective vaccine that is currently not available) is largely nonmodifiable,9 whereas body weight is at least somewhat modifiable. Thus, from a public health perspective, the results of this study continue to highlight that obesity prevention and maintenance of a healthy weight, especially earlier in life, remains a critical component in MS prevention in both subgroups of individuals with a higher MS risk (e.g., those with a family history of MS) as well as overall (because early-life obesity itself is a risk factor for MS).

Author contributions

K.C. Fitzgerald: drafting/revision of the manuscript for content, including medical writing for content. E.M. Mowry: drafting/revision of the manuscript for content, including medical writing for content.

Study funding

No targeted funding reported.

Disclosure

K.C. Fitzgerald has no disclosures. E.M. Mowry's institution has received research support from Biogen (for investigator-initiated study and for studies for which she is site PI) and Genzyme (for investigator-initiated study) and free medication for a clinical trial (of which she is PI) from Teva. She has received royalties for editorial duties from UpToDate. Go to Neurology.org/NN for full disclosures.

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • See page e912

  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Greenland S
    . Interactions in epidemiology: relevance, identification, and estimation. Epidemiology 2009;20:14–17.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Siemiatycki J,
    2. Thomas DC
    . Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol 1981;10:383–387.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Simon KC,
    2. van der Mei IaF,
    3. Munger KL, et al
    . Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010;74:1365–1371.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. De Jager PL,
    2. Simon KC,
    3. Munger KL,
    4. Rioux JD,
    5. Hafler DA,
    6. Ascherio A
    . Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008;70:1113–1118.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Hedström AK,
    2. Lima Bomfim I,
    3. Barcellos L, et al
    . Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 2014;82:865–872.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. de Heredia FP,
    2. Gómez-Martínez S,
    3. Marcos A
    . Obesity, inflammation and the immune system. Proc Nutr Soc 2012;71:332–338.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Grant RW,
    2. Dixit VD
    . Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015;23:512–518.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Olsson T,
    2. Barcellos LF,
    3. Alfredsson L
    . Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017;13:25–36.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Ascherio A,
    2. Munger KL,
    3. Lünemann JD
    . The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012;8:602–612.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology

Topics Discussed

  • All epidemiology
  • Multiple sclerosis
  • Risk factors in epidemiology

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology
    Anna Karin Hedström, Nicole Brenner, Julia Butt et al.
    Neurology: Neuroimmunology & Neuroinflammation, December 15, 2020
  • Articles
    Current and past Epstein-Barr virus infection in risk of initial CNS demyelination
    R.M. Lucas, A.-L. Ponsonby, K. Dear et al.
    Neurology, July 13, 2011
  • Article
    Elevated EBNA-1 IgG in MS is associated with genetic MS risk variants
    Karim L. Kreft, Gijsbert P. Van Nierop, Sandra M.J. Scherbeijn et al.
    Neurology: Neuroimmunology & Neuroinflammation, October 13, 2017
  • Article
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility
    A multiethnic study
    Annette Langer-Gould, Jun Wu, Robyn Lucas et al.
    Neurology, August 30, 2017
Neurology - Neuroimmunology Neuroinflammation: 10 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise